Reported about 19 hours ago
Sanofi's Riliprubart has been awarded orphan drug designation in Japan for treating chronic inflammatory demyelinating polyneuropathy (CIDP). This monoclonal antibody specifically targets activated C1s in the immune response, addressing a significant unmet medical need as around 30% of CIDP patients do not adequately respond to current treatments. Further studies are ongoing to assess Riliprubart's efficacy and safety, marking a key milestone for Sanofi in its pediatric treatment efforts.
Source: YAHOO